Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept conversion versus continued calcineurin inhibitor therapy in adolescent kidney transplant recipients
NL-OMON59657Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of belatacept in Kidney allograft status (RTx) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Survival with functional graft at 24 months. Started Sep 2022; status: recruiting.
02
Drugs
belatacept
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on NL-OMON59657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59657.